Pineal gland, melatonin and cancer

Neuroendocrinology Letters

Volumn 20, Issue 3-4, 1999, Pages 139-144

  Karasek, Michal ^a   Pawlikowski, Marek ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b NONE

Author keywords

Cancer; Malignant tumors; Melatonin; Neoplastic growth; Pineal gland

Indexed keywords

MELATONIN;

ADVANCED CANCER; BREAST CANCER; CANCER; COLORECTAL CARCINOMA; CONFERENCE PAPER; HUMAN; IMMUNE SYSTEM; MEDICAL RESEARCH; PINEAL BODY; PROSTATE CANCER; TUMOR GROWTH; UTERUS CANCER;

EID: 0032713458     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. Georgiou E. Uber die Natur und Pathogenese der Krebstumoren. Z Krebsforsch 1929; 28:562-72.
2. Blask DE. The pineal: An oncostatic gland. In: Reiter RJ, editor. The pineal gland. New York: Raven; 1984. p. 253-84.
3. Blask DE. Melatonin in oncology. In: Yu HS, Reiter RJ, editors. Melatonin - biosynthesis, physiological effects and perspectives. Boca Raton: CRC Press; 1993. p. 447-75.
4. Pawlikowski M, Karasek M. The pineal gland and experimentally-induced tumors. Adv Pineal Res 1990; 4:259-65.
5. Karasek M, Fraschini F. Is there a role of the pineal gland in neoplastic growth? In: Fraschini F, Reiter RJ, editors. Role of the pineal gland and melatonin in neuroimmunomodulation. New York: Plenum; 1991. p. 243-51.
6. Karasek M. Malignant tumors and the pineal gland. In: Gupta D, Wollmann HA, Fedor-Freybergh P, editors. Pathophysiology of immune-neuroendocrine communication circuit. Heidelberg: Mattes; 1994a. p. 225-44.
7. Karasek M. Relationship between the pineal gland and experimentally induced malignant tumors. Front Horm Res 1997; 23:99-106.
8. Karasek M. The pineal gland and neoplastic disease: Morphological aspects. Adv Pineal Res 1994b; 8:485-93.
9. Bartsch H, Bartsch C. Effect of melatonin on experimental tumors under different photoperiods and times of administration. J Neural Transm 1981; 52:269-79.
10. Chatteriee S, Benerji TK. Effects of melatonin on the growth of MtT/F4 anterior pituitary tumor: Evidence for inhibition of tumor growth dependent upon the time of administration. J Pineal Res 1989; 7:381-91.
11. Karasek M, Liberski P, Kunert-Radek J, Bartkowiak J. Influence of melatonin on the proliferation of hepatoma cells in the Syrian hamster: In vivo and in vitro study. J Pineal Res 1992; 13:107-10.
12. Lewinski A, Sewerynek E, Wajs E, Lopaczynski W, Sporny S. Effects of the pineal gland on the growth processes of Guerin epithelioma in male Wistar rats. Cytobios 1993; 73:89-94.
13. Guerrero JM. Mechanisms of action of melatonin on human lymphocytes. Proceedings of the Conference on Thymus and Pineal Gland in Neuroimmunoendocrinology, October 22-24. 1998; Swieradow, Poland (abstract, p. 28); 1998.
14. Lissoni P, Barni S, Tancini A, Ardizzoia M, Cazzaniga F, Frigerio F, et al. Neuroimmunomodulation of interleukin-2 cancer immunotherapy by melatonin: Biological and therapeutic results. Adv Pineal Res 1994; 7:183-9.
15. Lissoni P. Neuroimmunotherapy of human neoplasms with melatonin and antitumor cytokines. Int J Thymol 1996; 4(Suppl 1):84-7.
16. Reiter RJ. Functional aspects of the pineal hormone melatonin in combating cell and tissue damage induced by free radicals. Eur J Endocrinol 1996; 134:412-20.
17. Blask DE, Sauer LA, Dauchy RT, Holowachuk EW, Ruhoff MS. New insights into melatonin regulation of cancer growth. Proceedings of the Hanseatic Endocrine Conference: Melatonin After Four Decades: an Assessment of its Potential, August 24-30, 1998, Hamburg, Germany (abstract, p. 11); 1998.
18. Karasek M, Winczyk, Kunert-Radek J, Wiesenberg I, Pawlikowski M. Antiproliferative effects of melatonin and CGP 52608 on the murine colon 38 adenocarcinoma in vitro and in vivo. Neuroendocrinol Lett 1998; 19:71-8.
19. Wiesenberg I, Missbach M, Kahlen JP, Schraeder M, Carlberg C. Transcriptional activation of the nuclear receptor RZR by the pineal hormone melatonin and identification of CGP 52608 as a synthetic ligand. Nucleic Acid Res 1995; 23:327-33.
20. Carlberg C, Wiesenberg I ,Schrader M. Nuclear signalling of melatonin. Front Horm Res 1997; 23:25-35.
21. Becker-Andre Schaeren-Wiemers, Andre. Correction to the article: [Becker-Andre M et al. Pineal hormone melatonin binds and activates an orphan of the nuclear receptor superfamily J Biol Chem 1994; 269:28531-4]. J Biol Chem 1997; 272:16707.
22. Wiesenberg, Missbach, Saurat, Carlberg C. Addition to the article: (Becker-Andre M et al. J Biol Chem 1994; 269:28531-4]. J Biol Chem 1997; 272:16707.
23. Steinhilbel D, Brungs M, Werz O, Wiesenberg I, Danielsson C, Kahlen JP, et al. The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes. J Biol Chem 1995; 270:7037-40.
24. Melen-Mucha G, Winczyk K, Pawlikowski M. Somatostatin analogue octreotide and melatonin inhibit bromodeoxyuridine incorporation into cell nuclei and enhance apoptosis in the transplantable murine Colon 38 cancer. Anticancer Res 1998; 18:3615-20.
25. Karasek M. Melatonin and human neoplastic disease. Int J Thymol 1996; 4(Suppl 1):75-9.
26. Bartsch C, Bartsch H, Jain AK, Laurmas KR, Wetterberg L. Urinary melatonin levels in human breast cancer patients. J Neural Transm 1981; 52:281-94.
27. Bartsch C, Bartsch H, Fuchs U, Lippert TH, Bellmann O, Gupta D. Stage-dependent depression of melatonin in patients with primary breast cancer. Cancer 1989; 64:426-33.
28. Tamarkin L, Danforth D, Lichter A, De Moss E, Cohen M, Chabner B, et al. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science 1982; 216:1003-5.
29. Bartsch C, Bartsch H, Bellmann O, Lippert TH. Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. Cancer 1991; 67:1681-4.
30. Karasek M, Kuzdak K, Cywinski J, Zylinska K, Smialowska A, Pluzanska A. Effects of melatonin administration in advanced breast cancer patients - preliminary report. Neuroendocrinol Lett 1998; 19:15-9.
31. Bartsch C, Bartsch H, Fluchter SH, Harzmann R, Attanasio A, Bichler KH, et al. Circadian rhythms in serum melatonin, prolactin and growth hormone in patients with benign and malignant tumours of the prostate and non-tumours controls. Neuroendocrinol Lett 1983; 5:377-86.
32. Bartsch C, Bartsch H, Schmidt A, Ilg S, Bichler KH, Flüchter SH. Melatonin and 6-hydroxymelatonin circadian rhythms in serum and urine of primary prostete cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta 1992; 209:154-67.
33. Khoory R, Stemme D. Plasma melatonin levels in patients suffering from colorectal carcinoma. J Pineal Res 1988; 5:251-8.
34. Karasek M, Dec W, Kowalski AJ, Bartsch H, Bartsch C. Serum melatonin circadian profile in women with adenocorcinoma of uterine corpus. Int J Thymol 1996; 4(Suppl 1):80-3.
35. Lissoni P, Tancini G, Barni S, Crispino S, Paolorossi F, Rovelli F, et al. Melatonin increase as predictor for tumor objective response to chemotherapy in advanced cancer patients. Tumori 1988; 74:339-45.
36. Lissoni P, Barni S, Tancini A, Crispino S, Paolorossi F, Lucini V, et al. Clinical study of melatonin in untreatable advanced cancer patients. Tumori 1987; 73:475-80.
37. Lissoni P, Barni S, Crispino S, Tancini G, Fraschini F. Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncot 1989; 25:789-95.
38. Lissoni P, Barni S, Cattaneo G, Tancini G, Esposti G, Esposti D, et al. Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumour therapies. Oncology 1991; 48:448-50.